Evidence by goal

Peptides and muscle growth:
what has been tested?

Searches for “peptides for muscle growth” lead to BPC-157, TB-500, MOTS-c and follistatin. For each: what it is, the model it was studied in, its status with regulators and anti-doping rules, and what nobody knows yet.

Short answerCompound research · 7 min read · Updated 18 Nov 2026

We found no peptide medicine approved to build muscle in healthy people, and no FDA-approved drug for sarcopenia, age-related muscle loss (18 Nov 2026). The published muscle studies of BPC-157, thymosin β4 (the parent of TB-500) and MOTS-c were in rats and mice. The one myostatin-blocking medicine we found approved, the antibody apitegromab, is for spinal muscular atrophy only. WADA prohibits all of them.

Key takeaways

  • We found no peptide medicine approved to build muscle in healthy people, and a 2024 review states that FDA has approved no drug for sarcopenia.
  • FDA staff recorded in 2026 that TB-500, BPC-157 and MOTS-c are promoted online for uses that include muscle; the published muscle studies we found are in rats and mice. FDA staff found no article in which TB-500 was given to people; a later 2026 report describes three patients given it with BPC-157 and other agents, without a control group.
  • Antibodies that block the myostatin–activin pathway have reached people: apitegromab is FDA-approved for spinal muscular atrophy only, and in a trial of 180 older adults with sarcopenia the investigational antibody bimagrumab raised lean mass more than placebo, but physical performance did not differ.
  • WADA prohibits every compound on this page at all times: BPC-157 (S0), TB-500 (S2.3), apitegromab, bimagrumab and follistatin (S4.3) and MOTS-c (S4.4.1), in the 2026 and 2027 Lists.
  • Australia’s Poisons Standard (October 2026) lists BPC-157, TB-500, thymosin β4 and follistatin in Schedule 4 and Appendix D.

01Is any peptide approved for muscle growth?

Not that we found. We found no peptide medicine approved to build muscle in healthy people. A 2024 review of sarcopenia, the loss of muscle mass with age, states that “there are currently no drugs approved by the Food and Drug Administration for sarcopenia”. On 18 November 2026 no US drug label in FDA’s database listed sarcopenia in its indications, no label listed “muscle growth”, and the UK’s electronic medicines compendium returned nothing for sarcopenia. The one medicine we found approved that blocks myostatin, apitegromab (Isembyld), is an antibody, not a peptide, and FDA approved it on 11 September 2026 for spinal muscular atrophy in patients aged 2 and over who already receive an SMN2-targeted treatment: see below.

What is sold online as “peptides for muscle growth” is a different set of compounds. In its 2026 reviews for its compounding advisory committee, FDA staff recorded that TB-500, BPC-157 and MOTS-c are promoted online for a range of uses, muscle among them. None of the three is an FDA-approved medicine: Drugs@FDA lists no product containing any of them (18 Nov 2026).

Anabolic steroids are a different class of compound: see are peptides steroids? This page does not cover compounds that act on growth hormone.

02Which compounds have muscle studies, and in which models?

Each compound, the highest-tier muscle study we found, and its status, dated 18 November 2026. Tiers follow our evidence grades; sources are at the end of the page.

CompoundWhat it isHighest-tier muscle study we foundTierStatus: US · UK · Australia · sportWhat we don’t know
Apitegromab (Isembyld)Monoclonal antibody that targets the precursor forms of myostatin; not a peptideStudy 1 on its US label: randomised, double-blind, placebo-controlled; 188 patients aged 2 to 21 with spinal muscular atrophy, all on an SMN2-targeted treatment; about 1 year; motor function (HFMSE) measuredT1, approved for SMA onlyUS: approved 11 Sep 2026 (BLA 761463), spinal muscular atrophy only · UK: no emc entry · AU: no TGA Product Information found · WADA: S4.3 (named)Anything outside spinal muscular atrophy: its label covers no other use
BimagrumabInvestigational antibody that blocks activin type II receptors; not a peptideRooks et al., JAMA Network Open 2020: randomised, double-blind, placebo-controlled; 180 adults aged 70 and over with sarcopenia; 6 monthsT1, investigationalUS: no product in Drugs@FDA · UK: no emc entry · WADA: prohibited at all times, class S4.3 (named)Whether added lean mass improves function: in that trial, physical performance did not differ from placebo
Follistatin (sold online as “follistatin 344”)Protein that binds myostatin and activinLee and McPherron, PNAS 2001: transgenic mice made to produce extra follistatin in muscle; muscle mass measured. Mendell et al., Molecular Therapy 2015: gene transfer (AAV1.FS344), uncontrolled phase 1/2a, 6 patients with Becker muscular dystrophyT3; T2 for the gene-transfer studyUS: no product in Drugs@FDA · UK: no emc entry · AU: Schedule 4 and Appendix D, clause 5 (Poisons Standard Oct 2026) · WADA: S4.3 (named)What a manufactured follistatin product does in people: the human study used gene transfer, not the protein
BPC-157Synthetic peptide of 15 amino acidsStaresinic et al., Journal of Orthopaedic Research 2006: rats with a cut quadriceps muscle; strength, walking function and microscopy measured. A phase 2 placebo-controlled trial in hamstring strain (120 planned) is recruitingT3US: no product in Drugs@FDA · UK: no emc entry · AU: Schedule 4 and Appendix D, clause 5 · WADA: S0 (named)Any effect on muscle in people: the hamstring trial has no results
TB-500 and thymosin β4TB-500: a 7-amino-acid fragment of thymosin β4 in FDA’s documents. Thymosin β4: a 43-amino-acid proteinSpurney et al., PLoS One 2010: thymosin β4 (the full protein) given to exercised mdx mice, a model of Duchenne muscular dystrophy, for 6 months; regenerating fibres, grip strength, heart function and fibrosis measured. FDA staff found no article in which TB-500 was given to people; a later 2026 report describes three patients given it with BPC-157 and other agents, without a control groupT3US: no product in Drugs@FDA · UK: no emc entry for thymosin · AU: both in Schedule 4 and Appendix D, clause 5 · WADA: S2.3 (“Thymosin-β4 and its derivatives e.g. TB-500”)Any effect on muscle in people. The one registered TB-500 trial studies heart disease, not muscle
MOTS-cMitochondrial-derived peptide of 16 amino acidsReynolds et al., Nature Communications 2021: treadmill running in mice aged 2, 12 and 22 months (5 to 19 per group); grip strength and walking tests in old miceT3US: FDA staff say it is not a component of any FDA-approved drug · UK: no emc entry · AU: not named in the Poisons Standard (Oct 2026); we found no TGA statement applying any of its group entries to it and draw no scheduling conclusion of our own · WADA: S4.4.1 (named)Any effect in people: no published study has given it to people

03What has myostatin-pathway research measured, in animals and in people?

The pathway. Myostatin is a growth factor that, in the words of a 2001 paper, “acts as a negative regulator of skeletal muscle mass”. It binds activin type II receptors. Blocking that signal is the idea behind the antibodies below.

Apitegromab (approved for spinal muscular atrophy only). FDA approved Isembyld (apitegromab) on 11 September 2026. Its label describes a fully human monoclonal antibody that “targets proforms of myostatin”, indicated for spinal muscular atrophy in patients aged 2 and over who are already receiving an SMN2-targeted treatment. The label’s main trial randomised 188 patients aged 2 to 21 with spinal muscular atrophy to apitegromab or placebo for about a year and measured the change in a motor-function scale (HFMSE). The label warns that it “may increase the risk of fractures, including serious fractures”, and lists upper respiratory tract infections, vomiting, cough, headache and hypersensitivity among its most common adverse reactions. It is a prescription medicine for one disease, not a muscle-building product, and research-grade material sold online is not this medicine.

Follistatin (T3). In lab experiments, Lee and McPherron (PNAS, 2001) found that follistatin inhibited myostatin binding to its receptor. They then bred transgenic mice that made extra follistatin in muscle and measured their muscle mass. In 2015 a phase 1/2a study used gene transfer (AAV1.FS344) to deliver follistatin in six patients with Becker muscular dystrophy, with no control group, and measured the six-minute walk distance. Neither study gave people a manufactured follistatin protein.

Bimagrumab (T1, investigational). Bimagrumab is a fully human monoclonal antibody against activin type II receptors, not a peptide, and it is not approved. In a randomised, placebo-controlled trial of 180 adults aged 70 and over with sarcopenia, with adequate diet and home-based exercise in both groups, lean body mass rose 7% with bimagrumab and 1% with placebo over 6 months, but the primary measure, a physical-performance score, improved in both groups with no significant difference between them (Rooks et al., 2020). In RESILIENT, 251 adults with inclusion body myositis, a muscle disease, the six-minute walk distance at 52 weeks did not differ between bimagrumab and placebo; muscle spasms and diarrhoea were more frequent with bimagrumab, and serious adverse events were reported in 17% to 33% of the bimagrumab groups and 32% of the placebo group (Hanna et al., 2019). In a 2026 phase 2 obesity trial in 507 adults, the common adverse events of bimagrumab included muscle spasms, diarrhoea and acne.

Sport. WADA’s class S4.3, “agents preventing activin receptor IIB activation”, names apitegromab, bimagrumab and follistatin among its examples. They are prohibited at all times.

04What have BPC-157, TB-500 and MOTS-c muscle studies measured, and what do regulators say?

FDA staff found these three promoted online for muscle, among other uses. Their muscle studies are in animals; we describe the models and what was measured, not the authors’ findings.

BPC-157 (T3). In muscle-injury models, researchers cut the quadriceps muscle of rats (2006) or crushed the gastrocnemius muscle (2008), gave BPC-157, and measured healing by strength testing, walking function and microscopy. A 2025 systematic review of BPC-157 in orthopaedic sports medicine found 36 eligible studies, 35 of them preclinical, in models of muscle, tendon, ligament and bone injury. In people, a randomised, double-blind, placebo-controlled phase 2 trial in acute hamstring strain, planned for 120 participants, began in February 2026 and is recruiting; its primary outcomes are time to return to sport and the injury volume on MRI. It has no results. An uncontrolled study of a commercial product containing BPC-157, made by the study’s sponsor, in 40 physically active adults was completed in November 2025; it lists exercise-induced muscle damage among its conditions, measured blood markers of inflammation and self-reported swelling, and has posted no results. FDA staff, reviewing BPC-157 in 2026, found “insufficient clinical safety information to characterize the safety profile”, and wrote that as a peptide “administered through a parenteral or nasal” route it “may pose a significant risk for immunogenicity”. More: the BPC-157 guide.

TB-500 and thymosin β4 (T3). FDA staff wrote in 2026 that after a literature search “no articles were found in which TB-500 was administered to humans”. They concluded that “potential safety risks associated with the use of these substances in humans are unknown”, and that for the routes proposed in its nomination TB-500 “may pose a significant risk for immunogenicity”. A later report (2026) describes three dental patients with nerve injury who received TB-500 together with BPC-157 and other agents; with no control group, its authors write that causality “cannot be established”. The muscle study we found used the full 43-amino-acid protein, not TB-500: exercised mdx mice, a model of Duchenne muscular dystrophy, were given thymosin β4 for 6 months, and the researchers counted regenerating muscle fibres and measured grip strength, heart function and fibrosis (2010). The only registered TB-500 trial, a phase 1/2 study planned for 80 adults, is in stable atherosclerotic cardiovascular disease and measures adverse events. More: the TB-500 guide.

MOTS-c (T3). The group that described MOTS-c measured treadmill running in mice aged 2, 12 and 22 months (5 to 19 per group), and grip strength and walking tests in old mice (Reynolds et al., 2021). No published study has given MOTS-c to people. FDA staff found “a lack of evidence to evaluate the effectiveness” of MOTS-c for its nominated uses, which included “muscle/fat metabolism”, because the studies were “limited to in-vitro and in-vivo rodent models”, and they wrote that “potential safety risks associated with the use of MOTS-c in humans are unknown”. FDA’s compounding safety-risk page (content current 22 April 2026) says compounded drugs containing MOTS-c “may pose significant risk for immunogenicity for certain routes of administration”. More: the MOTS-c guide.

05How does WADA classify these compounds?

WADA’s Prohibited List names each compound on this page, and each is prohibited at all times, in and out of competition, in the 2026 and 2027 Lists.

  • S0, non-approved substances: BPC-157, named among examples of substances “with no current approval by any governmental regulatory health authority for human therapeutic use”.
  • S2.3, growth factors and growth factor modulators: “Thymosin-β4 and its derivatives e.g. TB-500”, and other growth factors “affecting muscle, tendon or ligament protein synthesis/degradation”.
  • S4.3, agents preventing activin receptor IIB activation: apitegromab, bimagrumab and follistatin, among others.
  • S4.4.1, metabolic modulators: MOTS-c, among activators of AMPK.

WADA’s explanatory note to the 2027 List adds: “Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health.” More: peptides and anti-doping.

06What we don’t know about peptides and muscle growth

  • Whether BPC-157, TB-500 or MOTS-c changes muscle in people. No controlled trial of any of them in muscle has published results. The placebo-controlled BPC-157 hamstring trial is recruiting, and an uncontrolled BPC-157 study that lists exercise-induced muscle damage among its conditions has posted no results.
  • Whether more lean mass means better function. In bimagrumab’s sarcopenia trial, lean mass rose more than with placebo, but physical performance did not differ.
  • What a manufactured follistatin product does in people. The human study we found used gene transfer.
  • What blocking myostatin does in healthy people. The trials on this page were in people with sarcopenia, muscle disease, spinal muscular atrophy or obesity.
  • What a vial sold online contains. Only a test of that sample can say.

Why we publish no doses for any compound: why we don’t publish doses.

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not medical or legal advice.

RefSources

  1. World Anti-Doping Agency. Prohibited List 2026 and Prohibited List 2027 (in force 1 Jan 2027): S0, S2.3, S4.3, S4.4.1; and the 2027 List summary of major modifications and explanatory notes. International Standard and explanatory note; PDFs downloaded from wada-ama.org 18 Nov 2026 (SHA-1 08b06d5a… and 8e84d248…), read 18 Nov 2026. www.wada-ama.org/en/prohibited-list
  2. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee, 23–24 July 2026: TB-500-related bulk drug substances (pp. 21, 32, 34). Advisory committee briefing, 2026; read 18 Nov 2026. www.fda.gov/media/193349/download
  3. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee, 23–24 July 2026: BPC-157-related bulk drug substances (pp. 23, 43). Advisory committee briefing, 2026; read 18 Nov 2026. www.fda.gov/media/193343/download
  4. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee, 23–24 July 2026: MOTS-c-related bulk drug substances (pp. 7, 20, 30–31). Advisory committee briefing, 2026; read 18 Nov 2026. www.fda.gov/media/193347/download
  5. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327): Schedule 4 and Appendix D, clause 5 entries for BPC-157, TB-500, thymosin β4 and follistatin; no entry for MOTS-c or bimagrumab. Federal Register of Legislation, commenced 1 Oct 2026; text searched 18 Nov 2026. www.legislation.gov.au/F2026L01327/latest/text
  6. Drugs@FDA via openFDA (no product for BPC-157, thymosin or timbetasin, MOTS-c, bimagrumab or follistatin) and FDA drug labels via openFDA (no indication containing “sarcopenia” or “muscle growth”); UK electronic medicines compendium searches for BPC-157, thymosin, follistatin, bimagrumab, apitegromab, MOTS-c and sarcopenia (no results); TGA Product Information search for apitegromab (no documents). Database queries, 18 Nov 2026. open.fda.gov/apis/drug/label/
  7. Isembyld (apitegromab-mstn) US prescribing information: §1, §5.1, §6, §11, §14; Drugs@FDA BLA 761463, original approval 11 Sep 2026. DailyMed setid b1cd8ab8-8a10-48ed-9806-75a44f22b963, effective 14 Sep 2026; read via openFDA 18 Nov 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1cd8ab8-8a…
  8. Zheng Y, Feng J, Yu Y, et al. Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies. Arch Pharm Res, 2024;47(4):301–324. PMID 38592582 (abstract read 18 Nov 2026). pubmed.ncbi.nlm.nih.gov/38592582/
  9. Rooks D, Swan T, Goswami B, et al. Bimagrumab vs optimized standard of care for treatment of sarcopenia in community-dwelling older adults: a randomized clinical trial. JAMA Netw Open, 2020;3(10):e2020836. PMID 33074327 (abstract read 18 Nov 2026); NCT02333331. pubmed.ncbi.nlm.nih.gov/33074327/
  10. Hanna MG, Badrising UA, Benveniste O, et al. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol, 2019;18(9):834–844. PMID 31397289 (abstract read 18 Nov 2026). pubmed.ncbi.nlm.nih.gov/31397289/
  11. Heymsfield SB, Aronne LJ, Montgomery P, et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nat Med, 2026;32(3):869–882. PMID 41772149 (abstract read 18 Nov 2026). pubmed.ncbi.nlm.nih.gov/41772149/
  12. Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A, 2001;98(16):9306–9311. PMID 11459935 (abstract read 18 Nov 2026). pubmed.ncbi.nlm.nih.gov/11459935/
  13. Mendell JR, Sahenk Z, Malik V, et al. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Mol Ther, 2015;23(1):192–201. PMID 25322757 (abstract read 18 Nov 2026). pubmed.ncbi.nlm.nih.gov/25322757/
  14. BPC-157 muscle-injury studies in rats: Staresinic M et al., [quadriceps transection model], J Orthop Res 2006;24(5):1109–1117 (PMID 16609979); Novinscak T et al., [gastrocnemius crush model], Surg Today 2008;38(8):716–725 (PMID 18668315); and Vasireddi N et al., Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review, HSS J 2025;21(4):485–495 (PMID 40756949). Abstracts read 18 Nov 2026. pubmed.ncbi.nlm.nih.gov/?term=16609979+OR+18668315+OR+407569…
  15. Spurney CF, Cha HJ, Sali A, et al. [Thymosin β4 in exercised mdx mice: skeletal and cardiac muscle measures.] PLoS One, 2010;5(1):e8976. PMID 20126456 (abstract read 18 Nov 2026). pubmed.ncbi.nlm.nih.gov/20126456/
  16. Reynolds JC, Lai RW, Woodhead JST, et al. [MOTS-c in mice of different ages, and natural MOTS-c levels in exercising men.] Nat Commun, 2021;12(1):470. PMID 33473109 (abstract read 18 Nov 2026; group sizes per full text PMC7817689). pubmed.ncbi.nlm.nih.gov/33473109/
  17. Froum S, Estrin N, Pico G, et al. [Narrative review with three uncontrolled clinical cases given several agents, including BPC-157 and TB-500.] Front Oral Health, 2026;7:1907109. PMID 42876687 (full text read 18 Nov 2026). pubmed.ncbi.nlm.nih.gov/42876687/
  18. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Web page, content current as of 22 Apr 2026; read 18 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  19. ClinicalTrials.gov: NCT07437547 (BPC-157, acute hamstring strain, phase 2, recruiting), NCT07752381 (BPC-157 product, single group, 40 physically active adults, completed November 2025, no results posted) and NCT07487363 (TB-500, stable atherosclerotic cardiovascular disease, phase 1/2, recruiting). Registry API v2, read 18 Nov 2026. clinicaltrials.gov/study/NCT07437547

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Is there an FDA-approved peptide for muscle growth?

We found none. A 2024 review states that FDA has approved no drug for sarcopenia, and on 18 November 2026 no US drug label in FDA’s database listed sarcopenia or muscle growth in its indications. Apitegromab, an antibody that blocks myostatin, is approved for spinal muscular atrophy only.

Has BPC-157 been tested on muscle injuries in people?

A randomised, placebo-controlled phase 2 trial in acute hamstring strain is registered and recruiting, with no results. An uncontrolled study of a commercial BPC-157 product in 40 physically active adults, completed in 2025, has posted no results. The published muscle-injury studies were in rats.

Has TB-500 been given to people?

FDA staff found no article in which TB-500 was given to humans (2026 review). A later 2026 report describes three dental patients who received TB-500 together with BPC-157 and other agents, with no control group; its authors write that causality “cannot be established”. One phase 1/2 trial is now recruiting, in heart disease rather than muscle.

Is follistatin a peptide?

It is a protein that binds myostatin. WADA lists it in class S4.3 as a myostatin-binding protein, and Australia’s Poisons Standard lists it in Schedule 4.

Are the compounds on this page prohibited in sport?

Every compound on this page is named on WADA’s Prohibited List and prohibited at all times. WADA adds that a peptide not named on the List “may still be prohibited”.

What did the bimagrumab sarcopenia trial measure?

In a trial of 180 adults aged 70 and over with sarcopenia, lean body mass rose 7% with bimagrumab and 1% with placebo, but physical performance did not differ between groups. It is an investigational antibody, not a peptide, and it is not approved.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page